Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Vera Therapeutics (Nasdaq: VERA), a late clinical-stage biotechnology company specializing in immunological disease treatments, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, scheduled for January 12-16, 2025.
The company's management team will deliver a presentation on Monday, January 13, 2025, at 4:30 PM PST. The presentation will be accessible via webcast, and investors can view it through the J.P. Morgan meetings platform. Additionally, the management team will engage in one-on-one meetings with investors during the conference.
A replay of the presentation will remain available for 90 days through the 'Investor Calendar' section of Vera Therapeutics' website.
Vera Therapeutics (Nasdaq: VERA), un'azienda biotecnologica in fase clinica avanzata specializzata nel trattamento delle malattie immunologiche, ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare che si terrà a San Francisco, CA, dal 12 al 16 gennaio 2025.
Il team di gestione dell'azienda presenterà un intervento lunedì 13 gennaio 2025, alle 16:30 PST. La presentazione sarà fruibile tramite webcast, e gli investitori potranno visualizzarla attraverso la piattaforma di incontri J.P. Morgan. Inoltre, il team di gestione avrà incontri in formato one-to-one con gli investitori durante la conferenza.
Un replay della presentazione sarà disponibile per 90 giorni nella sezione 'Calendario Investitori' del sito web di Vera Therapeutics.
Vera Therapeutics (Nasdaq: VERA), una empresa biotecnológica en etapa clínica avanzada especializada en tratamientos para enfermedades inmunológicas, ha anunciado su participación en la 43ª Conferencia Anual J.P. Morgan Healthcare que se llevará a cabo en San Francisco, CA, del 12 al 16 de enero de 2025.
El equipo de gestión de la empresa realizará una presentación el lunes 13 de enero de 2025, a las 4:30 PM PST. La presentación estará disponible a través de un webcast, y los inversores podrán verla a través de la plataforma de reuniones de J.P. Morgan. Además, el equipo de gestión participará en reuniones uno a uno con los inversores durante la conferencia.
Una repetición de la presentación estará disponible durante 90 días en la sección 'Calendario de Inversores' del sitio web de Vera Therapeutics.
베라 테라퓨틱스 (Nasdaq: VERA), 면역 질환 치료에 전문화된 임상 단계 후반의 바이오테크놀로지 회사는 제43회 JP 모건 헬스케어 컨퍼런스에 참여할 것이라고 발표했습니다. 이 행사는 2025년 1월 12일부터 16일까지 샌프란시스코에서 진행됩니다.
회사의 관리 팀은 2025년 1월 13일 월요일 오후 4시 30분 PST에 발표를 할 예정입니다. 발표는 웹캐스트를 통해 접근할 수 있으며, 투자자들은 JP 모건 미팅 플랫폼을 통해 이를 시청할 수 있습니다. 또한, 관리 팀은 컨퍼런스 동안 투자자들과 일대일 미팅을 진행할 예정입니다.
발표의 다시 보기는 베라 테라퓨틱스 웹사이트의 '투자자 일정' 섹션에서 90일 동안 이용할 수 있습니다.
Vera Therapeutics (Nasdaq: VERA), une entreprise de biotechnologie en phase clinique avancée spécialisée dans les traitements des maladies immunologiques, a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan Healthcare qui se tiendra à San Francisco, Californie, du 12 au 16 janvier 2025.
L'équipe de direction de l'entreprise fera une présentation le lundi 13 janvier 2025, à 16h30 PST. La présentation sera accessible par webinaire, et les investisseurs pourront la visionner via la plateforme de réunions de J.P. Morgan. De plus, l'équipe de direction participera à des réunions individuelles avec les investisseurs pendant la conférence.
Un replay de la présentation sera disponible pendant 90 jours dans la section 'Calendrier des Investisseurs' du site Web de Vera Therapeutics.
Vera Therapeutics (Nasdaq: VERA), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, das sich auf die Behandlung immunologischer Erkrankungen spezialisiert hat, hat seine Teilnahme an der 43. J.P. Morgan Healthcare-Konferenz in San Francisco, CA, angekündigt, die vom 12. bis 16. Januar 2025 stattfinden wird.
Das Management-Team des Unternehmens wird am Montag, den 13. Januar 2025, um 16:30 Uhr PST eine Präsentation halten. Die Präsentation wird über einen Webcast zugänglich sein, und die Investoren können sie über die J.P. Morgan Meetings-Plattform ansehen. Außerdem wird das Management-Team während der Konferenz persönliche Treffen mit Investoren durchführen.
Eine Wiederholung der Präsentation wird für 90 Tage im Bereich 'Investor Kalender' auf der Website von Vera Therapeutics verfügbar sein.
- None.
- None.
BRISBANE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present at the 43rd Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 12 – 16, 2025. The management team will also participate in one-on-one investor meetings.
Presentation Details:
Date: Monday, January 13, 2025
Time: 4:30 PM PST
Webcast: https://jpmorgan.metameetings.net/events/healthcare25
A replay of the event will be available for 90 days and can be accessed by visiting the “Investor Calendar” section of the Vera Therapeutics website.
About Vera
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit www.veratx.com.
For more information, please contact:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Madelin Hawtin
LifeSci Communications
MHawtin@lifescicomms.com
FAQ
When is Vera Therapeutics (VERA) presenting at the 2025 J.P. Morgan Healthcare Conference?
How long will the VERA J.P. Morgan Healthcare Conference presentation replay be available?
Where can investors access Vera Therapeutics' (VERA) J.P. Morgan Healthcare Conference presentation?
What type of investor engagement is VERA offering at the 2025 J.P. Morgan Healthcare Conference?
What is the duration of the 2025 J.P. Morgan Healthcare Conference where VERA is presenting?
